Bausch Health Companies Inc (BHC)
6.32
+0.15
(+2.43%)
USD |
NYSE |
Jun 14, 16:00
6.325
0.00 (0.00%)
After-Hours: 20:00
Bausch Health Enterprise Value: 24.60B for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 24.60B |
| June 13, 2024 | 24.55B |
| June 12, 2024 | 24.60B |
| June 11, 2024 | 24.52B |
| June 10, 2024 | 24.60B |
| June 07, 2024 | 24.58B |
| June 06, 2024 | 24.57B |
| June 05, 2024 | 24.59B |
| June 04, 2024 | 24.56B |
| June 03, 2024 | 24.60B |
| May 31, 2024 | 24.69B |
| May 30, 2024 | 24.59B |
| May 29, 2024 | 24.53B |
| May 28, 2024 | 24.56B |
| May 24, 2024 | 24.61B |
| May 23, 2024 | 24.61B |
| May 22, 2024 | 24.62B |
| May 21, 2024 | 24.68B |
| May 20, 2024 | 24.67B |
| May 17, 2024 | 24.77B |
| May 16, 2024 | 24.88B |
| May 15, 2024 | 24.88B |
| May 14, 2024 | 24.89B |
| May 13, 2024 | 24.90B |
| May 10, 2024 | 24.81B |
| Date | Value |
|---|---|
| May 09, 2024 | 24.83B |
| May 08, 2024 | 24.86B |
| May 07, 2024 | 25.00B |
| May 06, 2024 | 25.04B |
| May 03, 2024 | 25.15B |
| May 02, 2024 | 25.25B |
| May 01, 2024 | 25.49B |
| April 30, 2024 | 25.50B |
| April 29, 2024 | 25.54B |
| April 26, 2024 | 25.48B |
| April 25, 2024 | 25.44B |
| April 24, 2024 | 25.42B |
| April 23, 2024 | 25.41B |
| April 22, 2024 | 25.38B |
| April 19, 2024 | 25.47B |
| April 18, 2024 | 25.44B |
| April 17, 2024 | 25.46B |
| April 16, 2024 | 25.49B |
| April 15, 2024 | 25.45B |
| April 12, 2024 | 25.49B |
| April 11, 2024 | 25.57B |
| April 10, 2024 | 25.55B |
| April 09, 2024 | 25.68B |
| April 08, 2024 | 25.84B |
| April 05, 2024 | 26.10B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
23.16B
Minimum
May 12 2023
35.62B
Maximum
Mar 11 2021
28.60B
Average
29.61B
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 5.205M |
| Aurinia Pharmaceuticals Inc | 457.57M |
| Edesa Biotech Inc | 11.51M |
| Lexaria Bioscience Corp | 34.65M |
| Xenon Pharmaceuticals Inc | 2.112B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.00M |
| Revenue (Quarterly) | 2.153B |
| Total Expenses (Quarterly) | 1.859B |
| EPS Diluted (Quarterly) | -0.17 |
| Gross Profit Margin (Quarterly) | 70.27% |
| Profit Margin (Quarterly) | -2.97% |
| Earnings Yield | -19.62% |
| Operating Earnings Yield | 72.26% |
| Normalized Earnings Yield | -2.792 |